(Q27851532)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803 (English)

2 references

13 November 2016

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Leonard B. Saltz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

2

Jeffrey A Meyerhardt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

14

Charles S Fuchs

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

3

Natsumi Irahara

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

4

Donna Niedzwiecki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

5

Donna Hollis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

8

Paul Schaefer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

9

Renaud Whittom

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

10

Alexander Hantel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

13

Monica M Bertagnolli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Robert J Mayer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Al B Benson

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Richard M Goldberg

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Cancer and Leukemia Group B

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

North Central Cancer Treatment Group

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Canadian Cancer Society Research Institute

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Southwest Oncology Group

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

24 November 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

published in

Clinical Cancer Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

7322-7329

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

12 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

KRAS mutations: an old oncogene becomes a new predictive biomarker

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Targeted therapy of cancer: new roles for pathologists in colorectal cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Molecular classification and correlates in colorectal cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Sensitive sequencing method for KRAS mutation detection by Pyrosequencing

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Genetic alterations in locally advanced stage II/III colon cancer: a search for prognostic markers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Systematic review of genetic influences on the prognosis of colorectal cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

The prevalence of PIK3CA mutations in gastric and colon cancer.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2787689

Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis

27 November 2018

1 reference

12 December 2020

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

12 December 2020

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803

1 reference

12 December 2020

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone

1 reference

12 December 2020

10.1158/1078-0432.CCR-09-1570

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19934290%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

2 references